Press Releases - Daiichi Sankyo US
WEB18 hours ago · Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in March 2019 and datopotamab deruxtecan (Dato-DXd) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and datopotamab ...
AstraZeneca and Daiichi Sankyo report data from Phase III breast …
WEB7 hours ago · AZN. 4568.T. AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato ...
Astra, Daiichi Suffer New Setback With Mixed Cancer Drug Results ...
WEB11 hours ago · September 23, 2024 at 3:10 AM EDT. Save. AstraZeneca Plcsaid an experimental cancer drug it’s developing with Daiichi Sankyo Co.did not help breast cancer patients live longer than chemotherapy ...
U.S. News Room - Daiichi Sankyo US
WEB6 days ago · About Daiichi Sankyo ... This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s ...
AstraZeneca's experimental drug disappoints in breast cancer …
WEB11 hours ago · AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...
Readout Newsletter: Biohaven, Daiichi Sankyo, AstraZeneca news …
WEB5 hours ago · Daiichi Sankyo and AstraZeneca said the experimental cancer treatment Dato-DXd failed to prolong survival of participants in the TROPION-Breast01 clinical trial. Previously, the companies reported ...
Daiichi Sankyo and MSD’s ADC improves progression-free …
WEB5 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with ...
NHS England to offer Daiichi Sankyo’s quizartinib for AML
WEB3 days ago · In this article: 4568.T. The National Health Service (NHS) England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML) patients with the FLT3 ...
U.S. News Room - Daiichi Sankyo US
WEBFebruary 19, 2024. Application based on results from the TROPION-Lung01 phase 3 trial. If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate for patients with lung cancer.
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid ...
WEBSep 16, 2024 · Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of its investigational antibody-drug conjugate (ADC) DS-9606 for treating advanced solid tumours. Developed in collaboration with the Tokyo University of Pharmacy and Life Sciences, DS-9606 is designed using Daiichi Sankyo ...